Paper Details

  1. Home
  2. Paper Details

Multiple sclerosis therapeutic pipeline: opportunities and challenges.

Author: KriegerStephen

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Oral medications are becoming increasingly important in the treatment of multiple sclerosis (MS). The approval of dalfampridine and fingolimod in 2010 marked the beginning of this trend. Other oral medications under development include cladribine, teriflunomide, laquinimod, and dimethyl fumarate. Monoclonal antibodies are also being investigated, including alemtuzumab, daclizumab, and rituximab. These drugs have the potential to offer new treatment options for MS patients, but they can also have side effects. It is important to carefully monitor patients who take these drugs for potential side effects, such as opportunistic infections, cancers, and other systemic consequences of immunosuppression. Because there are many different treatment options available, it is important to choose the best treatment for each individual patient.
Paper Details　
Original Abstract of the Article :
The year 2010 marked the beginning of the era of oral medications for the treatment of multiple sclerosis, with the approval of dalfampridine to improve walking and fingolimod as the first oral disease-modifying agent. This review provides an overview of these and other emerging therapies, with an e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/msj.20241

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Multiple Sclerosis Treatment

Multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system, can be likened to a vast and unpredictable desert, where individuals face a constant battle against the debilitating effects of this condition. This study delves into the evolving landscape of MS therapies, examining the opportunities and challenges presented by emerging treatments.

A New Oasis of Treatment Options

The researchers discuss the recent approval of oral medications for MS, marking a significant shift in treatment paradigms. They explore the potential of various therapies under development, including non-selective immunosuppressants, targeted immune-modulators, and monoclonal antibodies. This exploration highlights the exciting advancements in MS research and the promise of new treatment options for individuals struggling with this challenging disease.

Balancing the Benefits and Risks

The study also acknowledges the potential side effects and adverse events associated with these emerging therapies, emphasizing the need for careful monitoring and management. The researchers discuss the importance of individualized treatment approaches, recognizing the diverse needs and responses of individuals living with MS.

Dr. Camel's Conclusion

This study offers a comprehensive overview of the expanding therapeutic landscape for multiple sclerosis, highlighting the potential of new treatment paradigms and the challenges they pose. The researchers' insights underscore the need for careful consideration of individual patient characteristics, risk factors, and potential side effects when selecting and managing MS therapies. Imagine a vast desert, where the shifting sands represent the complex and ever-changing nature of MS. This study provides a roadmap for navigating this challenging terrain, guiding us towards more effective and personalized treatment approaches for individuals living with this disease.
Date :
  1. Date Completed 2011-07-27
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21425264

DOI: Digital Object Identifier

10.1002/msj.20241

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.